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Post-transplant lymphoproliferative disease (PTLD) is a major complication of clinical organ and cell trans-
plantation. Conditioning and immunosuppressive regimens that signiﬁcantly impair T cell immunity,
including depleting antibodies and calcineurin inhibitors, increase the risk of PTLD after transplantation.
Swine PTLD has been shown to closely resemble human PTLD in morphology, histology, and viral-driven
reactivation of B cells. Previously, we reported high incidences of PTLD after hematopoietic cell trans-
plantation (HCT) in miniature swine recipients conditioned with thymic irradiation (TI) in addition to T cell
depletion and cyclosporine A monotherapy after transplantation. Replacement of TI with 100 cGy of total
body irradiation resulted in similar numbers of B cells early post-transplantation, greater numbers of T cells at
day 0, and markedly decreased incidence of PTLD, suggesting that a threshold number of T cells may be
necessary to prevent subsequent B cell proliferation and development of overt PTLD. Results from this large
cohort of animals provide insight into the important effect of irradiation and T cell immunity on the incidence
of PTLD after HCT and reinforce the pig model as a valuable tool for the study of PTLD and HCT.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION models of PTLD involving immunodeﬁcient mice injected
Post-transplant lymphoproliferative disease (PTLD) is a
potentially lethal complication of clinical organ and cell
transplantation, as a consequence of prolonged immuno-
suppression [1]. In humans, PTLD is characterized by an
abnormal B cell proliferation related to Epstein-Barr virus
primary infection or reactivation. Conditioning regimens
that diminish T cell immunity, such as thymoglobulin
mediated Tcell depletion or long-term calcineurin inhibition,
increase the risk of PTLD after transplantation. This risk re-
sults from the loss of antiviral function of CD8þ cytotoxic
T cells, which are primarily responsible for suppressing
Epstein-Barr viruseassociated infections [2]. The variability
of the human patient population, both clinically and patho-
logically, complicates the ability to study PTLD. Murineedgments on page 1737.
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ty for Blood and Marrow Transplantation.with human PTLD lines and mice infected with murine
gamma herpesvirus [3,4] are often unreliable and do not
model human disease accurately. Therefore, large animal
preclinical models that mimic human PTLD provide an op-
portunity to identify risk factors and investigate therapeutic
approaches to mitigate this frequently lethal condition.
We have previously reported a high incidence (>33%) of
PTLD in swine after hematopoietic cell transplantation (HCT)
that closely resembles human PTLD bothmorphologically and
histologically [5,6]. In this model recipients were conditioned
with T cell depletion using a porcine CD3 immunotoxin and
cyclosporine A (CyA) monotherapy with or without thymic
irradiation (TI; 700 to 1000 cGy). Risk factors for the devel-
opment of PTLD in this model, which are similar to those in
humans, were also described, including the effects of periph-
eral blood chimerism levels, T cell depletion, TI, immunosup-
pression levels, and MHC disparity [6]. We also identiﬁed a
novel porcine lymphotropic herpesvirus-1 (PLHV-1) associ-
ated with PTLD in swine, paralleling human infection with
Epstein-Barr virus [7]. Theseﬁndings further support thepig as
a reliable preclinical large animal model of PTLD.
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Figure 1. PTLD incidence. Incidence of PTLD in animals that received a con-
ditioning regimen with SCF/IL3 þ no irradiation (-), SCF/IL3 þ TBI (A), SCF/
IL3 þ TI (:), or G-CSF þ TBI (;). *P < .05.
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model, we replaced high-dose TI as part of the preparative
regimen with low-dose 100 cGy of total body irradiation
(TBI). In this study, we report on the effect of irradiation (TBI
versus TI) on the incidence of PTLD in our miniature swine
model and also demonstrate that serum lactate dehydroge-
nase (LDH) levels serve as a supportive marker for the
diagnosis of PTLD in swine.
METHODS
Animals
This is a retrospective study of all animals conditioned for HCT at the
Transplantation Biology Research Center at Massachusetts General Hospital
using a porcine CD3 immunotoxin for recipient T cell depletion and a short
course of CyA since 1997. All animals that developed PTLD were diagnosed
between 21 and 45 days post-HCT. Therefore, only animals who survived at
least 45 days post-HCT were selected for this analysis, unless early death
was due to PTLD. Animals were selected from our herd of Massachusetts
General Hospital partially inbredMHC-deﬁnedminiature swine, which have
been previously described [8]. Transplant donors ranged from 4 to 6 months
in age and recipient animals from 8 to 12 weeks. All experiments were
approved and performed in compliance with the Institutional Animal Care
and Use Committee.
Irradiation
When administered, animals received either 100 cGy of TBI or 1000 cGy
of TI as previously described [9]. Because only 4 animals received 700 cGy TI
in 1997 before the protocol was changed to 1000 cGy TI, we decided to
exclude these 4 animals from the PTLD analysis in this study. Animals were
sedated, and a cobalt irradiator was used for all regimens. The dose was
calculated dependent on the source decay charts.
T Cell Depletion and CyA
Animals receiving no irradiation or TI were administered .05 mg/kg CD3
immunotoxin, pCD3-CRM9 [10], on day 2 for T cell depletion. Animals
receiving TBI were either administered .05 mg/kg CD3 immunotoxin, pCD3-
CRM9, on day 2 (n ¼ 13) or .05 mg/kg recombinant CD3-immuntoxin
(pCD3-rIT) [11] twice daily 8 hours apart beginning on day 4 until
day 1 (n ¼ 27). CyA was administered orally through a gastrostomy tube
twice daily with target levels of 400 to 800 ng/mL in all animals
commencing on day 1 and concluding on either day 30 or 60 for those
animals receiving TI or day 30 followed by a 2-week taper for those animals
receiving TBI.
Hematopoietic Cell Transplantation
HCT was performed as previously described [12]. Brieﬂy, transplant
donors were mobilized once daily with porcine IL-3 (100 mg/kg/day) and
porcine stem cell factor (SCF; 100 mg/kg/day) or with human granulocyte
colony-stimulating factor (G-CSF; 10 mg/kg/day) beginning on day 5. Pe-
ripheral blood mononuclear cells (PBMCs) were harvested by leukapheresis
beginning on day 0. Cytokine injections were continued, and donor animals
were leukapheresed daily for up to 3 days until the target cell dose of 1 to
15  109 cells/kg of recipient body weight was collected. After each leuka-
pheresis collection, fresh cells were infused intravenously into recipient
animals over 15 to 20 minutes.
PTLD Diagnosis
A diagnosis of PTLD was made based on a combination of ﬂow cyto-
metric conﬁrmation of B cell lymphoproliferation and physical signs and
symptoms, including loss of appetite, lethargy, and lymphadenopathy. In the
case of death, conﬁrmation of PTLD diagnosis was made by histologic
analysis. All recipients that developed PTLDwere diagnosed between 21 and
45 days post-HCT.
Flow Cytometry
Flow cytometry was performed on a weekly basis to monitor myeloid
and B cell proliferation, chimerism levels, and percent and absolute T cell
counts in the peripheral blood. Methods were previously described [5,6].
Brieﬂy, chimerism levels were assessed by the use of pig allelic antigen, a
nonspeciﬁc cell marker present on donor cells but not on host cells. Donor
and hosts were speciﬁcally screened before transplant, and only pig allelic
antigenepositive donors and pig allelic antigenenegative hosts were
selected. B cell lymphoproliferation and absolute B cell numbers were
monitored by assessing the CD3/CD16 double-negative population as
previously described [5,6].Graft-versus-Host Disease Assessment
Graft-versus-host disease (GHVD) was assessed daily by physical exam
in all animals. Total bilirubin and liver enzymes (alanine and aspartate
aminotransferases and alkaline phosphatase) were assessed biweekly (or
more often if medically indicated). Any rash was documented, and skin was
biopsied and assessed via histopathology if deemed appropriate. Gastroin-
testinal signs of GVHD were assessed clinically by fecal volume (animals
housed in metabolic cages) and consistency (watery, mucoidal, mucohe-
morrhagic, etc). Additionally, rectal biopsies were taken if clinically indi-
cated and compared with pretransplant samples. Twice weekly, donor and
host T cells were assessed via ﬂow cytometry. A Seattle scoring system was
developed in swine and used to standardize GVHD assessment (developed
in conjunction with Dr. Thomas R. Spitzer- director of the Massachusetts
General Hospital unit). A description of this GVHD swine scoring system and
the characterization of the miniature swine GVHD is forthcoming (Duran-
Struck et al, unpublished data).
LDH ELISA
PBMCs were isolated from heparinized blood by Ficoll gradient centri-
fugation and cultured for 18 hours with or without phytohemagglutinin
(M Form; Invitrogen, Carlsbad, CA, USA). Cells were plated at 1  103 to
5  104 cells per well, and total LDH was determined using the Lactic De-
hydrogenase based In Vitro Toxicology Assay Kit (Sigma Aldrich, St. Louis,
MO, USA). This assay has been previously described [13].
Statistical Analysis
A 1-sample t-test was used to assess whether the leukocyte counts were
higher among the PTLD animals than the mean of the normal range under
the assumption of unknown variance. A 2-sample t-test was used to
compare the distribution of LDH levels between the PTLD animals versus
healthy controls under the assumption of unequal variances. The P values
were based on a 2-sided hypothesis test and computed using Stata 7.0 (Stata
Corp, College Station, TX). Survival curves were plotted using Kaplan-Meier
estimates using a log rank (Mantel-Cox) test. P < .05 was considered sta-
tistically signiﬁcant.
RESULTS
Effect of Irradiation on Incidence of PTLD after HCT
Beginning in 1997, 29 miniature swine received SCF/IL3
mobilized HCTs after conditioning with 1000 cGy TI, T cell
depletion with pCD3-CRM9, and a short course of CyA (30 to
60 days), with a PTLD incidence rate of 34.4% (10/29)
(Figure 1). In an attempt to reduce post-transplant compli-
cations including PTLD in this model of HCT, TI was removed
from the protocol, which resulted in a decreased incidence of
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Figure 2. T cell depletion. Level of T cell depletion in animals on day 0 after
receiving a conditioning regimen with CD3 immunotoxin and either no irra-
diation (n ¼ 16), 1000 cGy TI (n ¼ 28), or 100 cGy TBI (n ¼ 37). Absolute CD3þ
T cells from naive swine are provided for comparison.
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very mild preparatory regimen consisting of only CD3-
immunotoxin and CyA monotherapy without TI resulted in
reduced Tcell depletion (Figure 2), andmany animals failed to
engraft long term [14]. As a result,100 cGy of TBI was added to
the conditioning protocol with the intention of providing
additional immunosuppression and/or bone marrow space to
enhance engraftment, while also depleting radiosensitive
B cells. In 40 subsequent HCTs of SCF/IL3mobilized cells,12.5%
(5/40) developed PTLD (Figure 1). Thirty-seven animals were
transplanted across a single-haplotypemismatch and 3 across
a 2-haplotype mismatch with PTLD incidences of 10.8% (4/37)
and 33.3% (1/3), respectively (Table 1).No Effect of Mobilization and T Cell Depletion Strategies
on PTLD
Using a different mobilization strategy, 19 animals un-
derwent the same conditioning regimenwith Tcell depletion
and 100 cGy TBI but received G-CSF mobilized cells. All 19
were transplanted across a single-haplotype mismatch and
had a PTLD incidence of 21% (4/19) (Table 1 and Figure 1).
Among the animals in the TBI groups, there was no signiﬁ-
cant difference (P ¼ .38) in PTLD incidence between re-
cipients of G-CSF versus SCF/IL3 mobilized cells (Figure 1). In
total, 59 animals underwent reduced-intensity conditioning
with 100 cGy TBI and were transplanted with either SCF/IL3
(n¼ 40) (Figure 1) or G-CSF (n¼ 19) (Table 1) mobilized cells,
with an overall PTLD incidence rate of 15.2% (9/59).
As described in Methods, 2 different CD3 immunotoxins
were used during the course of this study. pCD3-CRM9 wasTable 1
MHC Disparity and PTLD Incidence
No Irradiation
SCF/IL-3 (No. Developing
PTLD; PTLD Incidence)
TI
SCF/IL-3 (No.
PTLD; PTLD In
No mismatch 2 (0; 0%) 1 (0; 0%)
Single-haplotype mismatch 16 (1; 6.2%) 14 (5; 35.6%)
Two-haplotype mismatch 5 (0; 0%) 14 (5; 35.6%)
Total 23 (1; 4.3%) 29 (10; 34.4%substituted for pCD3-rIT for safety reasons unrelated to this
study and the development of PTLD. Animals receiving no
irradiation (n ¼ 23) and TI (n ¼ 29) received T cell depletion
with pCD3-CRM9 on day 2. Among 40 animals receiving
SCF/IL3 þ TBI, 13 animals received T cell depletion with
pCD3-CRM9 on day 2 and 27 with pCD3-rIT twice daily
from days 4 to 1 (Supplementary Figure 1B,C). Of the 5
animals in the SCF/IL3 þ TBI group who developed PTLD
post-transplant, 4 of 27 (14.8%) had been conditioned with
pCD3-rIT and 1 of 13 (7.8%) with pCD3-CRM9. All 19 animals
in the G-CSF þ TBI group received pCD3-CRM9, with 4 (21%)
developing PTLD. Although the overall number of animals
is limited, our results support that pCD3-CRM9 versus
pCD3-rIT had no statistically signiﬁcant effects on PTLD
development (Supplementary Figure 1B,C).
The majority of PTLD in the TI group was of host type
lymphoproliferation (9/10). Of the 9 total animals that
developed PTLD in the TBI group, data on the origin of PTLD
was only available in 3 animals, of which 2 were host origin
and 1 was donor origin (Supplementary Figure 2).
Length of CyA Treatment and PTLD
We compared the incidence of PTLD among the different
groups based on the length of CyA treatment. Among the TI
group, 12 of 29 animals received a 30-day course of CyA and
the remaining 17 were scheduled to receive a 60-day course.
Three of 12 animals (25%) that received CyA for 30 days
developed PTLD. All were diagnosed early after the discon-
tinuation of immunosuppression (days 30, 32, and 35). Of the
remaining 17 animals scheduled for a 60-day CyA course, 7
(41%) developed PTLD (CyA was subsequently decreased or
discontinued in these animals). All of them developed PTLD
early post-HCT (days 21, 26, 34, 34, 40, 45, and 48). Among
the 40 animals in the SCF/IL3 þ TBI group, all received a
45-day course of CyA, which included continuous dosing
through day 30 followed by a 2-week taper to day 45. Five of
40 developed PTLD (12.5%). Similarly, all 19 animals in the
G-CSFþ TBI group also received a 45-day course of CyA, with
4 (21%) developing PTLD. We did not ﬁnd a correlation
between length of CyA and development of PTLD post-
transplant (Supplementary Figure 1A).
MHC Mismatch and PTLD
Within the TI group, where the incidence of PTLD was
greatest, we did not observe any signiﬁcant difference in
incidence among animals that were transplanted across
single-haplotype MHC barriers (5/14; 35.7%) compared with
those transplanted across 2-haplotype MHC barriers (5/14;
35.7%) (Table 1). Within the TBI group, animals transplanted
across a single-haplotype MHC barrier appeared to have a
lower incidence of PTLD (4/37 or 10.8%) than those trans-
planted across 2 MHC haplotype barriers (1/3 or 33.3%).
However, the total number of animals developing PTLD
(n ¼ 5) and the total number of animals transplanted acrossDeveloping
cidence)
TBI
SCF/IL-3 (No. Developing
PTLD; PTLD Incidence)
TBI
G-CSF (No. Developing
PTLD; PTLD Incidence)
0 0
37 (4; 10.8%) 19 (4; 21.1%)
3 (1; 33.3%) 0
) 40 (5; 12.5%) 19 (4; 21.1%)
Figure 3. Comparison between absolute T cell numbers in animals with and without PTLD after receiving different conditioning regimens. (A) Post-HCT day 0 ab-
solute T cell counts in animals treated with TI. (B) Absolute T cell counts on post-HCT day 0 after conditioning with TBI. (C) Absolute T cell counts 2 weeks post-HCT in
animals that received SCF/IL3 with TBI.
A.J. Matar et al. / Biol Blood Marrow Transplant 21 (2015) 1732e1738 17352-haplotype MHC barriers (n ¼ 3) among the TBI group are
too small to make any conclusions regarding this point
(Table 1).
Effect of Lymphocyte Depletion and Recovery on Incidence
of PTLD
Absolute counts of T cells on day 0 in animals conditioned
with TI, 0.45  103/uL  0.35 (n ¼ 28), were found to be
signiﬁcantly lower (P ¼ .04) than those conditioned with TBI,
0.57  103/uL  0.33 (n ¼ 37) (Figure 2). However, there was
no signiﬁcant difference in absolute T cell numbers at day
0 between those animals developing PTLD, 0.39  103/
uL 0.47 (n¼ 11), and those that did not, 0.41103/uL 0.28
(n ¼ 21), within the TI group (Figure 3A). In contrast, the day
0 Tcell counts were found to be signiﬁcantly lower (P¼ .03) in
the animals that developed PTLD, 0.5  103/uL  0.38 (n ¼ 6),
than those that did not, 1.0  103/uL  0.29 (n ¼ 6), within
the group that received TBI (Figure 3B). Conversely, absolute
T cell recovery measured at 2 weeks in the same group
revealed no signiﬁcant differences between animals that
developed PTLD from those that did not (Figure 3C). A com-
parison of absolute B cell numbers at 1 and 2 weeks post-HCT
between animals in the TI versus TBI groups showed nosigniﬁcant differences (data not shown). A limitation of this
analysis, however, is that B cell datawere available fromonly 4
animals in the TI group at these early time points.
Serum LDH is a Reliable Marker in the Diagnosis of PTLD
in Miniature Swine
Retrospective analysis of serum LDH levels was per-
formed in 17 HCT recipients, regardless of conditioning
regimen. Mean LDH level at the time of PTLD diagnosis in 9
animals that developed PTLD (6034 U/L) was signiﬁcantly
higher than in 8 HCT recipients that did not develop PTLD
(1392 U/L) when analyzed at similar time points
(Figure 4A). Furthermore, analysis of serum taken before
any clinical presentation of lymphadenopathy showed an
increase in LDH level at the time of WBC increase in ani-
mals that developed PTLD (Figure 4B). Previously, we
reported the establishment of porcine PTLD tumor cell lines
[15]. We analyzed 5 porcine PTLD tumor cell lines for pro-
duction of LDH in vitro and compared with LDH production
from normal PBMCs in vitro. PTLD cell lines secreted
greater amounts of LDH than PBMCs as measured by ELISA
(0.2 optical density versus mean 0.4 optical density)
(Figure 4C).
Figure 4. LDH. (A) Representative serum LDH levels (U/L) at the time of PTLD diagnosis (6034 U/L) compared with serum LDH levels in animals without PTLD (1392
U/L) (P ¼ .0002). (B) Representative data of serum LDH levels over time from pre-HCT to clinical lymphadenopathy in an animal (18861) developing PTLD. (C) LDH
levels detected by ELISA in 5 previously established porcine PTLD tumor cell lines (14736, 13271, 15446, 17016L [lymph node origin], 17016P [peritoneal origin], 17018)
compared with LDH levels from normal peripheral blood leukocytes. Statistical signiﬁcance with a P < .0001 between groups marked with different number of
asterisks (*). Groups that have the same number (*) are not statistically signiﬁcant between each other.
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We previously reported that a novel HCT protocol
consisting of 700 to 1000 cGy TI, T cell depletion with
pCD3-CRM9, and CyA monotherapy resulted in high PTLD
incidence rates (>33%) [5,6]. Removal of TI reduced the
incidence of PTLD, but, similarly to the TI group, poor long-
term engraftment outcomes were observed. Subsequently,
100 cGy TBI was introduced to the preparative regimen in
an attempt to improve donor cell engraftment while
simultaneously hypothesizing that the effect of TBI on
peripheral B cells would minimize the risk of developing
PTLD. This change signiﬁcantly reduced the incidence of
PTLD while improving long-term engraftment outcomes
without increasing the incidence of GVHD in our model
12% (Duran-Struuck et al., unpublished data). One hy-
pothesis for improved donor cell engraftment upon intro-
duction of TBI is the increased “space” in the marrow
niches provided by TBI mediated ablation of hematopoietic
cells [16,17].In comparison with solid organ transplantation, reac-
tivation (or de novo infection) of PLHV-1 and development of
PTLD after allogeneic HCTgenerally appears early in the post-
transplant period when T cell responses are blunted [18].
Thus, limiting the period of impaired T cell immunity after
transplantation is a critical component in preventing PTLD.
Using our reduced-intensity conditioning regimen, animals
regain T cell immunity within 7 weeks after transplantation
demonstrated by third-party cell mediated lympholysis
reactions (data not shown). Furthermore, absolute T cell
numbers are only transiently reduced and begin to recover
within 10 to 14 days after transplantation (data not shown).
We initially hypothesized that the combination of greater
levels of T cell depletion in the animals receiving 1000 cGy TI
and the lack of any direct effect on B cells contributed to
uncontrolled B cell proliferation and the development of
PTLDdmost likely stimulated via PLHV-1 viral infection or
reactivation. Although not signiﬁcant enough to make a
conclusion because of the limited numbers of animals in the TI
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2 weeks post-HCT from animals in each group (TI versus TBI)
showed no differences. These preliminary data showing no
apparent differences in B cell numbers contradict our initial
hypothesis that the 100-cGy TBI regimen, and not the 1000-
cGy TI regimen, would reduce host B cell numbers directly.
Although peripheral blood B cell numbers were similar early
post-transplantation, it is possible that animals receiving TBI
may have had signiﬁcantly lower numbers of B cells present in
lymphoid tissues not sampled such as the lymph nodes or
spleen. The dose of TBI used in this study is far less damaging
to the thymus and thus may explain the difference in absolute
T cell numbers between the 2 groups. Based on these data, it
may be that a threshold number of T cells (and potentially
sparing memory T cells) at day 0 are required to prevent
subsequent B cell proliferation and development of overt
PTLD. It is important to note that unlike other antibodies such
as antithymocyte globulin, CD3 immunotoxin has signiﬁcant
depleting effects on thymic T cells, mitigating the need for TI
in protocols already including CD3 immunotoxin [19].
We have previously reported on the incidence of PLHV-1
in our miniature swine herd, noting that its incidence in-
creases with the age of the animal [6]. We previously esti-
mated that 19% of young recipients (6 to 8 weeks of age) test
positive for PHLV-1 and 55% of donors (4 to 6 months of age)
test positive. Importantly, we found no correlation between
pretransplant positive PLHV-1 status (either in donor or
recipient) and post-transplant development of PTLD.
Cyclosporine monotherapy was used post-transplantation
in all animals. Although the varying lengths of post-transplant
immunosuppression courses could have played a role in PTLD
incidence, all animals (who did not die of PTLD before day 30)
received CyA immunosuppression for at least 30 days. This
length of immunosuppression is sufﬁcient to allow for the
development of PTLD, as demonstrated by 4 of 11 who
received TI and developed clinical PTLD before day 30.
Moreover, 3 animals receiving 30-day courses of CyA were
actually diagnosed on or after day 30 (days 30, 32, and 35).
As described, there was no signiﬁcant difference in PTLD
incidence among animals that were transplanted across
single-haplotype MHC barriers (5/14; 35.7%) compared with
those transplanted across 2 haplotype MHC barriers (5/14;
35.7%) in the TI group (Table 1). Within the TBI group, ani-
mals transplanted across a single haplotype MHC barrier
appeared to have a lower incidence of PTLD (4/37 or 10.8%)
than those transplanted across 2 MHC haplotype barriers (1/
3 or 33.3%). However, as was stated, the distribution of the
animals developing PTLD (n ¼ 5) was limited by the total
number of animals transplanted across 2 haplotype MHC
barriers (n ¼ 4). However, there was a noteworthy difference
in the distribution of single- versus 2-haplotype mismatches
among the TI and TBI groups. Fourteen of 29 animals (48.2%)
in the TI group were transplanted across a 2-haplotype
mismatch, whereas only 3 of 40 animals (7.5%) in the TBI
groupwere transplanted across a 2-haplotype mismatch. We
acknowledge that this variable may have had an inﬂuence on
PTLD incidence, because MHC disparity may be another
contributing factor. However, when comparing animals
receiving the same mobilization regimen (SCF/IL3) and
transplanted across a single-haplotype mismatch (14 ani-
mals in the TI group and 37 in the TBI group), animals
receiving TBI had lower incidences of PTLD (10.8% versus
35.7%) than those in the TI group.
Similar to humans, serum LDH has already been shown to
be elevated in swine chronic myeloid leukemias, but thiscorrelation has not yet been demonstrated in swine PTLD
B cell lymphomas until now. We have also previously
demonstrated the similarity of porcine PTLD to human PTLD
with respect to viral driven activation, morphologically and
histologically [5,6]. Here we provide evidence that LDH can
also serve as a supportive diagnostic marker for PTLD lym-
phomas. In our swine, the increase of LDH can be detected at
least 1 to 2 days before the increase in WBC count and well
before any clinical manifestation of lymphadenopathy.
Therefore, similarly to human PTLD [20], rising serum LDH
levels after transplantation can be an indicator of a lym-
phoproliferative process.
In summary, large animal models can be an invaluable
tool for the study of PTLD after allogeneic HCT. This report
provides insight into the effects of irradiation on the inci-
dence of PTLD after HCT. Reduced-intensity conditioning
regimens using 1000 cGy TI dramatically reduce T cell
numbers, resulting in a signiﬁcant incidence of PTLD. The
addition of 100 cGy TBI appears to be protective of PTLD by
maintaining a sufﬁcient number of T cells in the host pe-
riphery, and preliminary data suggest this protective mech-
anism is not based on greater B cell depletion. Based on these
outcomes, we report that the addition of 100 cGy TBI mini-
mizes the risk of PTLD compared with 1000 cGy TI while
allowing for acceptable levels of engraftment and a low
incidence of GVHD. The use of pre-emptive low-dose total
body irradiation warrants further inquiry in speciﬁc immu-
nosuppressive regimens.
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